AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis

Autoimmunity

Volumn 42, Issue 4, 2009, Pages 302-304

  Nienhuis, Hans L A ^a   Westra, Johanna ^a   Smit, Andries J ^a   Limburg, Pieter C ^a   Kallenberg, Cees G M ^a   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

AGE; Atherosclerosis; Inflammation; RAGE; Systemic autoimmune diseases

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HEPARIN; MYELOPEROXIDASE; PATTERN RECOGNITION RECEPTOR;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL COMMUNICATION; CELL FUNCTION; CHRONIC INFLAMMATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOMODULATION; MACROPHAGE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLUBILITY; SYNOVIAL FLUID; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; VASCULITIS;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; RECEPTORS, IMMUNOLOGIC;

EID: 70749087658     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930902831746     Document Type: Short Survey

References (21)

1. Smit AJ, Lutgers HL. The clinical relevance of AGE and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767-2784.
2. Nienhuis HL, de Leeuw K, Bijzet J, et al. Skin autofluorescence is increased in SLE but is not reflected by elevated plasma levels of AGE. Rheumatology (Oxford) 2008;47: 1554-1558.
3. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. RAGE is induced by AGE themselves and TNF-a through NF-kB, and by 17beta-estradiol through Sp-1 in HUVEC. J Biol Chem 2000;275:25781-25790.
4. Zhong Y, Li SH, Liu SM, et al. CRP upregulates RAGE expression in human endothelial cells. Hypertension 2006;48: 504-511.
5. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apoE-null mice. Circulation 2002;106:2827-2835.
6. Basta G. RAGE and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
7. Basta G, Lazzerini G, Massaro M, et al. AGE activate endothelium through RAGE: A mechanism for amplification of inflammatory responses. Circulation 2002;105:816-822.
8. Chavakis T, Bierhaus A, Al Fakhri N, et al. RAGE is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003;198: 1507-1515.
9. Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE. Binding of RAGE ligands is not sufficient to induce inflammatory signals: Lack of activity of endotoxin-free albumin-derived AGE. Diabetologia 2004;47:844-852.
10. Ballinger ML, Thomas MC, Nigro J, Ivey ME, Dilley RJ, Little PJ. Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney Int 2005;68:2756-2765.
11. Buetler TM, Leclerc E, Baumeyer A, et al. N(epsilon)- carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008;52:370-378.
12. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of RAGE expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.
13. Raucci A, Cugosi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolitic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM 10). FASEB J. 2008;22(10):3716-3727.
14. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of sRAGE and circulating AGE in T2DM. Diabetologia 2006;49: 2756-2762.
15. Bopp C, Hofer S, Weitz J, et al. sRAGE is elevated in septic patients and associated with patients ouTCome. J Surg Res 2008;147:79-83.
16. Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE are associated with inflammatory markers in patients with T2DM. Mol Med 2007;13:185-189.
17. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. sRAGE triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006;54:3898-3907.
18. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'Angelo A. High levels of sRAGE may be a marker of extreme longevity in humans. J Am Geriatr Soc 2006;54: 1149-1150.
19. Gross S, van Ree RM, Oterdoom LH, et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation 2007;84:659-663.
20. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of sRAGE and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-1037.
21. Renard C, Chappey O, Wautier MP, et al. The human and rat recombinant RAGE have a high degree of homology but different pharmacokinetic properties in rats. J Pharmacol Exp Ther 1999;290:1458-1466.